Finance
Results: 26053-26064 of 49949

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

ESTEVE signs a licensing agreement for a severe primary insulin-like growth factor 1 deficiency treatment





